Sponsor

Astellas Pharma Global Development Inc.

United States 2375 Waterview Drive, 60062-6145, United States

About the sponsor

Research activity centers on gastric cancer, gastroesophageal junction adenocarcinoma, metastatic pancreatic adenocarcinoma, and related advanced solid tumors, with emphasis on tumors defined by CLDN18.2 expression and HER2-negative disease.

Gastric adenocarcinoma
Gastroesophageal junction adenocarcinoma
CLDN18.2-positive tumors
Metastatic pancreatic adenocarcinoma

The portfolio also includes studies in locally advanced unresectable and metastatic upper gastrointestinal disease.

About Specializations

Astellas Pharma Global Development Inc. runs clinical trials in conditions such as Adenocarcinoma gastric, Oesophageal adenocarcinoma, Acute myeloid leukaemia, Ductal adenocarcinoma of pancreas, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Quick filters

19 clinical trials

Ductal adenocarcinoma of pancreas

Recruiting

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

A Study of Setidegrasib with Chemotherapy Drug Combination as First‑Line Treatment in Adults with KRAS G12D‑mutated Metastatic Pancreatic Cancer

Investigational

France

Participants:18–64 years · 65+ years
Substances:ASP3082
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Bladder cancer

Recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

Study of Enfortumab Vedotin and Pembrolizumab for Bladder Preservation in Patients with Muscle‑Invasive Bladder Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Enfortumab Vedotin
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Prostate cancer metastatic

Recruiting

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Study on Long-Term Safety of Enzalutamide, Abiraterone, and Prednisolone for Patients with Prostate Cancer from Previous Enzalutamide Trials

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Abiraterone
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug

Belgium

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Non-small cell lung cancer+1

Not yet recruiting

Study of setidegrasib (ASP3082) and docetaxel in patients with KRAS G12D‑mutated advanced/metastatic NSCLC after platinum chemo and checkpoint inhibitor

Registered drugNo placebo